Inspire Medical Systems (NYSE:INSP) Updates FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.750-1.250 for the period, compared to the consensus earnings per share estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.

Inspire Medical Systems Trading Down 1.8%

Shares of NYSE INSP opened at $47.37 on Wednesday. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of 10.57, a P/E/G ratio of 2.83 and a beta of 0.83. Inspire Medical Systems has a 1-year low of $44.41 and a 1-year high of $163.35. The stock’s 50-day moving average is $56.51 and its 200 day moving average is $79.43.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.66%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, analysts forecast that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INSP. UBS Group set a $67.00 target price on Inspire Medical Systems in a report on Friday, February 13th. Zacks Research downgraded Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Mizuho decreased their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday. Truist Financial lowered their target price on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $85.00.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat on the headline numbers: reported EPS $0.10 (vs. consensus -$0.28) and revenue $204.6M (vs. ~$200M), showing core business resilience. Q1 Results
• Neutral Sentiment: Management hosted an earnings call and provided additional color on operational headwinds (coding timing, reimbursement uncertainty, and the WISeR program rollout) — useful for investors parsing the guidance assumptions. Earnings Call Transcript
• Negative Sentiment: Company materially cut FY2026 guidance: revenue $825M–$875M (vs. ~ $961M consensus) and EPS $0.75–$1.25 (vs. ~ $1.99 consensus), citing reimbursement/coding disruptions and WISeR-related procedure softness — the guidance reset is the primary driver of the share decline. Guidance & Headwinds
• Negative Sentiment: Multiple analysts cut price targets and adjusted ratings following the guidance reset (examples: Mizuho to $55, Robert W. Baird to $50, JPMorgan to $54, Wells Fargo to $56, Truist to $50); the analyst re-pricing amplifies selling pressure. Mizuho PT Cut Baird PT Cut
• Negative Sentiment: Editorial/analyst commentary turned more cautious—Seeking Alpha published a continued “Sell” view after the earnings/guidance update, reflecting concerns about near-term growth and execution risk. Sell Rating Commentary

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its stake in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after purchasing an additional 205 shares during the period. Daiwa Securities Group Inc. lifted its holdings in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 130 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after acquiring an additional 638 shares during the last quarter. Quarry LP boosted its position in shares of Inspire Medical Systems by 695.1% during the fourth quarter. Quarry LP now owns 644 shares of the company’s stock worth $59,000 after acquiring an additional 563 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in Inspire Medical Systems by 349.7% during the fourth quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock valued at $66,000 after acquiring an additional 556 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.